

Mark L Warren

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/810549/publications.pdf>

Version: 2024-02-01

8
papers

5,089
citations

1307366
7
h-index

1588896
8
g-index

8
all docs

8
docs citations

8
times ranked

5029
citing authors

#	ARTICLE	IF	CITATIONS
1	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 1834-1844.	13.9	3,898
2	Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2019, 381, 841-851.	13.9	1,002
3	Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline <scp>BMI</scp> or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2210-2219.	2.2	87
4	Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2291-2297.	2.2	38
5	Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: <scp>PRONTO&Pump</scp>. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1552-1561.	2.2	25
6	Insulin Degludec 200 Units/mL Is Associated With Lower Injection Frequency and Improved Patient-Reported Outcomes Compared With Insulin Glargine 100 Units/mL in Patients With Type 2 Diabetes Requiring High-Dose Insulin. <i>Clinical Diabetes</i> , 2017, 35, 90-95.	1.2	18
7	Semaglutide improves health-related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (<scp>SUSTAIN</scp> 6). <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1339-1347.	2.2	18
8	Patient-reported outcomes from a randomized, crossover trial comparing a pen injector with insulin degludec versus a pen injector with insulin glargine U100 in patients with type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2019, 35, 1623-1629.	0.9	3